U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C22H26O4
Molecular Weight 354.4394
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SERATRODAST

SMILES

CC1=C(C)C(=O)C(C(CCCCCC(O)=O)C2=CC=CC=C2)=C(C)C1=O

InChI

InChIKey=ZBVKEHDGYSLCCC-UHFFFAOYSA-N
InChI=1S/C22H26O4/c1-14-15(2)22(26)20(16(3)21(14)25)18(17-10-6-4-7-11-17)12-8-5-9-13-19(23)24/h4,6-7,10-11,18H,5,8-9,12-13H2,1-3H3,(H,23,24)

HIDE SMILES / InChI
Molecular Formula C22H26O4
Molecular Weight 354.4394
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: Description was created based on several sources, including: http://www.tabletwise.com/seradair-tablet https://www.1mg.com/drugs/seretra-80-mg-tablet-130697

Seratrodast belongs to a class of medication called thromboxane A2/prostaglandin endoperoxide receptor antagonist. Seratrodast blocks the broncho-constrictor effects of certain chemicals (prostaglandins) in the body. Seratrodast also decreases the inflammation by antagonising the thromboxane A2 receptor. Adverse effects include gastrointestinal disturbances, drowsiness, headache, palpitations, and hepatitis. Seradair may interact with Ozagrel.

Originator

Takeda Chemical Industries
28
Curator's Comment: # Takeda Chemical Industries, Ltd.

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2778
 60.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
Bronica

Approved Use

Seratrodast is used for the prevention and treatment of mild to moderate asthma.
PubMed

PubMed

TitleDatePubMed
Mechanisms underlying cerebrovascular effects of cigarette smoking in rats in vivo.
1998 Aug
Long-term observations of the clinical course after step down of corticosteroid inhalation therapy in adult chronic asthmatics: correlation with serum levels of eosinophil cationic protein.
2002 Sep
Patents

Patents

CN100999452 B
1
US5180742 A
1

Sample Use Guides

In Vivo Use Guide
Curator's Comment: In elderly patients it is recommended that the treatment should be started with a lower dose of 40 mg/day.
It is given in single doses of 80 mg in the evening after food.
Route of Administration: Oral
In Vitro Use Guide
Sources: DOI: 10.1111/j.1527-3466.1996.tb00231.x
Seratrodast competitively inhibited the contractile response to U-46619, PGD2, 9-alpha, 11beta-PGF2, or PGF2-alpha with pA2 values of 7.69, 7.20, 7.79, and 5.71, respectively.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:54:00 UTC 2023
Edited
by admin
on Fri Dec 15 15:54:00 UTC 2023
Record UNII
4U58JM421N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SERATRODAST
INN   JAN   MART.   MI   USAN   WHO-DD  
INN   USAN  
Official Name English
SERATRODAST [JAN]
Common Name English
(±)-2,4,5-TRIMETHYL-3,6-DIOXO-.ZETA.-PHENYL-1,4-CYCLOHEXADIENE-1-HEPTANOIC ACID
Systematic Name English
ABBOTT 73001
Code English
Seratrodast [WHO-DD]
Common Name English
AA-2414
Code English
BRONICA
Brand Name English
SERATRODAST [MI]
Common Name English
seratrodast [INN]
Common Name English
ABBOTT-73001
Code English
ABT-001
Code English
BENZENEHEPTANOIC ACID, .ZETA.-(2,4,5-TRIMETHYL-3,6-DIOXO-1,4-CYCLOHEXADIEN-1-YL)-, (±)-
Common Name English
NSC-759640
Code English
(±)-7-(3,5,6-TRIMETHYL-1,4-BENZOQUINON-2-YL)-7-PHENYLHEPTANOIC ACID
Systematic Name English
SERATRODAST [USAN]
Common Name English
SERATRODAST [MART.]
Common Name English
A-73001
Code English
Classification Tree Code System Code
WHO-ATC R03DX06
Created by admin on Fri Dec 15 15:54:00 UTC 2023 , Edited by admin on Fri Dec 15 15:54:00 UTC 2023
WHO-VATC QR03DX06
Created by admin on Fri Dec 15 15:54:00 UTC 2023 , Edited by admin on Fri Dec 15 15:54:00 UTC 2023
NCI_THESAURUS C29712
Created by admin on Fri Dec 15 15:54:00 UTC 2023 , Edited by admin on Fri Dec 15 15:54:00 UTC 2023
Code System Code Type Description
FDA UNII
4U58JM421N
Created by admin on Fri Dec 15 15:54:00 UTC 2023 , Edited by admin on Fri Dec 15 15:54:00 UTC 2023
PRIMARY
SMS_ID
100000084135
Created by admin on Fri Dec 15 15:54:00 UTC 2023 , Edited by admin on Fri Dec 15 15:54:00 UTC 2023
PRIMARY
EPA CompTox
DTXSID4021397
Created by admin on Fri Dec 15 15:54:00 UTC 2023 , Edited by admin on Fri Dec 15 15:54:00 UTC 2023
PRIMARY
USAN
HH-41
Created by admin on Fri Dec 15 15:54:00 UTC 2023 , Edited by admin on Fri Dec 15 15:54:00 UTC 2023
PRIMARY
ChEMBL
CHEMBL70972
Created by admin on Fri Dec 15 15:54:00 UTC 2023 , Edited by admin on Fri Dec 15 15:54:00 UTC 2023
PRIMARY
WIKIPEDIA
SERATRODAST
Created by admin on Fri Dec 15 15:54:00 UTC 2023 , Edited by admin on Fri Dec 15 15:54:00 UTC 2023
PRIMARY
NCI_THESAURUS
C90671
Created by admin on Fri Dec 15 15:54:00 UTC 2023 , Edited by admin on Fri Dec 15 15:54:00 UTC 2023
PRIMARY
DRUG CENTRAL
2432
Created by admin on Fri Dec 15 15:54:00 UTC 2023 , Edited by admin on Fri Dec 15 15:54:00 UTC 2023
PRIMARY
EVMPD
SUB10490MIG
Created by admin on Fri Dec 15 15:54:00 UTC 2023 , Edited by admin on Fri Dec 15 15:54:00 UTC 2023
PRIMARY
CAS
112665-43-7
Created by admin on Fri Dec 15 15:54:00 UTC 2023 , Edited by admin on Fri Dec 15 15:54:00 UTC 2023
PRIMARY
MERCK INDEX
m9868
Created by admin on Fri Dec 15 15:54:00 UTC 2023 , Edited by admin on Fri Dec 15 15:54:00 UTC 2023
PRIMARY Merck Index
NSC
759640
Created by admin on Fri Dec 15 15:54:00 UTC 2023 , Edited by admin on Fri Dec 15 15:54:00 UTC 2023
PRIMARY
INN
7069
Created by admin on Fri Dec 15 15:54:00 UTC 2023 , Edited by admin on Fri Dec 15 15:54:00 UTC 2023
PRIMARY
PUBCHEM
2449
Created by admin on Fri Dec 15 15:54:00 UTC 2023 , Edited by admin on Fri Dec 15 15:54:00 UTC 2023
PRIMARY
MESH
C060230
Created by admin on Fri Dec 15 15:54:00 UTC 2023 , Edited by admin on Fri Dec 15 15:54:00 UTC 2023
PRIMARY
DRUG BANK
DB06739
Created by admin on Fri Dec 15 15:54:00 UTC 2023 , Edited by admin on Fri Dec 15 15:54:00 UTC 2023
PRIMARY
Related Record Type Details
THROMBOXANE A2 RECEPTOR
TARGET -> INHIBITOR
POTENCY
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 2C19
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 2B6
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 2C8
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
Structure of 5-METHYLHYDROXY SERATRODAST
METABOLITE -> PARENT
in human liver microsomes
MAJOR
Structure of 4'-HYDROXYSERATRODAST
METABOLITE -> PARENT
in human liver microsomes
MINOR
Related Record Type Details
Structure of SERATRODAST
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966